Distinct acute myeloid leukemia subclasses with CEBPA mutations

具有 CEBPA 突变的不同急性髓系白血病亚类

• 批准号: 7406094
• 负责人: DANIEL G TENEN
• 金额: $ 38.99万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-12 至 2012-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7406094
• 关键词: Acute Myelocytic Leukemia; Acute leukemia; Adult Acute Myeloblastic Leukemia; Applications Grants; Blast Cell; Blood Cells; CCAAT-Enhancer-Binding Protein-alpha; CEBPA gene; Cell Differentiation process; Characteristics; Classification; Data; Development; Diagnostic; Failure; Future; Gene Expression; Gene Targeting; Genes; Goals; Hematopoietic; Human; Knowledge; Laboratories; Lead; Leukemic Cell; Link; Malignant Neoplasms; Molecular; Mutation; Myelogenous; Myeloid Cells; Myeloid Leukemia; Myelopoiesis; Pathogenesis; Pathway interactions; Patients; Pattern; Phenotype; Play; Process; Proteins; Public Health; Range; Research; Research Personnel; Role; Testing; Therapeutic Intervention; Transcription Factor 3; Translating; base; factor C; human disease; in vivo; leukemia; mutant; novel; prognostic; programs; tool; transcription factor

DESCRIPTION (provided by applicant): Knowledge of the mechanisms underlying the normal development of blood cells will lead to new understanding of the pathogenesis of acute leukemias. The long range goals are to further our understanding of the mechanisms involved in leukemia, to develop new prognostic classifications based on molecular mechanisms, and then to experimentally validate these target genes and pathways in order to eventually develop more specific, less toxic therapies for leukemia and other cancers. The transcription factor C/EBP alpha is absolutely critical for differentiation of normal myeloid blasts, and disrupted (mutations or decreased expression) in specific subtypes of AML. Recent studies have demonstrated distinct gene expression clusters in patients with mutations in C/EBP alpha, as well as new target genes. Over the next 5 years, we propose to establish that these clusters can be utilized for new prognostic strategies, as well as to understand more about the mechanism of how mutations of C/EBP alpha lead to a block in differentiation in order to develop strategies for specific treatments based on knowledge of the molecular mechanisms. We therefore propose the following Specific Aims: (1) To characterize human AML clusters whose gene expression pattern is characteristic of C/EBP alpha mutations ("C/EBP alpha clusters"); (2) To study the mechanisms by which C/EBP alpha mutant proteins fail to induce granulocytic differentiation; and (3) To test the function of C/EBP alpha mutant protein in vivo. These studies will lead to novel prognostic tools, as well as the identification of novel target pathways for therapeutic intervention in the future. Relevance of this research to public health: The aim of this research is to better understand the genes involved in the development of acute myeloid leukemia (AML) in order to develop better diagnostic and prognostic tools as well as new therapies. In this proposal, we will characterize a specific type of AML, one that is characterized by abnormalities in a gene called C/EBP alpha, which in non-leukemic cells directs the differentiation process. We will develop diagnostic tools to identify these patients, as well as study the mechanisms of how the failure of the abnormal C/EBP alpha gene product to direct differentiation leads to the development of leukemia.

描述（由申请人提供）：了解血细胞正常发育的机制将导致对急性白血病发病机制的新认识。长期目标是进一步了解白血病的机制，发展基于分子机制的新的预后分类，然后通过实验验证这些靶基因和途径，以便最终开发出针对白血病和其他癌症的更具体、毒性更小的治疗方法。转录因子C/EBP α对正常髓母细胞的分化至关重要，在AML的特定亚型中被破坏（突变或表达减少）。最近的研究表明，在C/EBP α突变患者中存在不同的基因表达簇，以及新的靶基因。在接下来的5年里，我们建议建立这些集群可以用于新的预后策略，以及更多地了解C/EBP α突变如何导致分化阻断的机制，以便根据分子机制的知识制定特定的治疗策略。因此，我们提出以下具体目标：(1)表征基因表达模式具有C/EBP α突变特征的人类AML集群（“C/EBP α集群”）；(2)研究C/EBP α突变蛋白诱导粒细胞分化失败的机制；(3)在体内检测C/EBP α突变蛋白的功能。这些研究将导致新的预后工具，以及未来治疗干预的新靶标途径的确定。本研究与公共卫生的相关性：本研究的目的是更好地了解参与急性髓性白血病（AML）发展的基因，以便开发更好的诊断和预后工具以及新的治疗方法。在这个提议中，我们将描述一种特定类型的AML，其特征是一种名为C/EBP α的基因异常，该基因在非白血病细胞中指导分化过程。我们将开发诊断工具来识别这些患者，并研究异常C/EBP α基因产物引导分化失败导致白血病发展的机制。